Zoetis Inc. (NYSE:ZTS) Holdings Lifted by Cetera Investment Advisers

Cetera Investment Advisers increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 275.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,085 shares of the company’s stock after buying an additional 70,476 shares during the quarter. Cetera Investment Advisers’ holdings in Zoetis were worth $16,259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ZTS. Norges Bank bought a new position in shares of Zoetis in the fourth quarter worth about $980,646,000. Price T Rowe Associates Inc. MD grew its stake in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares during the period. Swedbank AB acquired a new position in shares of Zoetis in the 1st quarter worth approximately $210,815,000. Public Employees Retirement Association of Colorado acquired a new position in shares of Zoetis in the 4th quarter worth approximately $242,757,000. Finally, CIBC Private Wealth Group LLC lifted its holdings in Zoetis by 122.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock worth $285,923,000 after buying an additional 797,884 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on ZTS. Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group lowered their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Stifel Nicolaus lowered their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. BTIG Research assumed coverage on shares of Zoetis in a report on Thursday, July 25th. They set a “buy” rating and a $220.00 price target for the company. Finally, HSBC cut their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus price target of $212.67.

Zoetis Trading Down 1.0 %

NYSE:ZTS opened at $180.59 on Friday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The company’s 50-day simple moving average is $175.44 and its 200 day simple moving average is $175.60. The firm has a market capitalization of $82.40 billion, a P/E ratio of 34.80, a PEG ratio of 2.80 and a beta of 0.86.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.31 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.96%. Zoetis’s payout ratio is 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.